Skip to main content

Table 2 Enquiry types and motivations to call for DMARDs versus ROC

From: Real-world questions and concerns about disease-modifying antirheumatic drugs (DMARDs): a retrospective analysis of questions to a medicine call center

 All DMARDs
(n = 1547)
(%)
cDMARD
(n = 1269)
(%)
bDMARDs
(n = 278)
(%)
ROC
(n = 121,709)
(%)
Enquiry type
 Side-effects25.2†27.2†15.1†‡19.6
 Interaction19.4†21.9†6.5†‡15.1
 Risk/Benefit & comparison12.1†12.5†9.7‡8.3
 Mechanism / Profile9.5†8.415.8†‡7.0
 Indication & treatment10.510.510.811.9
 Dose & administration6.06.72.5†‡7.9
 Efficacy3.12.85.8†‡2.8
 Availability3.01.411.2†‡2.6
 Pregnancy & lactation2.9†3.1†1.8†8.6
 Cost and PBS access2.00.78.2†‡1.4
 Identification / Formulation1.91.24.7‡3.4
 Stability/Storage/Disposal1.30.64.7†‡0.9
 Abuse and withdrawal1.41.50.4†3.4
 Generics0.40.30.70.8
 Vaccination0.70.70.71.9
 Outside service brief (e.g.0.10.101.5
 poisons query)    
 Non-medicines issue0.60.51.12.
Motivation to call
 Inadequate information44.044.057.7†‡46.6
 Second opinion23.623.618.4†‡23.5
 Worrying symptom18.818.813.4†‡17.8
 Conflicting information6.9†6.9†1.7†‡~ 0
 Information overload2.32.31.71.2
 CMI0.90.90.10.5
 Forgot information0.70.71.30.1
 Media1.21.23.4†‡0.9
 Health professionals0.50.50.86.3
 Other1.11.11.71.7
  1. PBS Pharmaceutical Benefits Scheme, CMI Consumer Medicines Information
  2. p < 0.05 versus ROC, with Bonferroni correction
  3. p < 0.05 versus cDMARDs